EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 218 / Numéro 1-2 (2024) Biologie Aujourd’hui, 218 1-2 (2024) 41-54 References
Free Access
Issue
Biologie Aujourd’hui
Volume 218, Number 1-2, 2024
Page(s) 41 - 54
DOI https://doi.org/10.1051/jbio/2024007
Published online 15 juillet 2024
  • Ackerman, L., Acloque, G., Bacchelli, S., Schwartz, H., Feinstein B.J., La Stella, P., Alavi, A., Gollerkeri, A., Davis, J., Campbell, V., McDonald, A., Agarwal, S., Karnik, R., Shi, K., Mishkin, A., Culbertson, J., Klaus, C., Enerson, B., Massa, V., Kuhn, E., Sharma, K., Keaney, E., Barnes, R., Chen, D., Zheng, X., Rong, H., Sabesan, V., Ho, C., Mainolfi, N., Slavin, A., A. Gollob, J.A. (2023). IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nature Med, 29, 3127-3136. [Google Scholar]
  • Ahn, G., Banik, S.M., Miller, C.L., Riley, N.M., Cochran, J.R., Bertozzi, C.R. (2021). LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol, 17, 937-946. [Google Scholar]
  • Ahn, G., Riley, N.M., Kamber, R.A., Wisnovsky, S., von Hase, S.M., Bassik, M.C., Banik, S.M., Bertozzi, C.R. (2023). Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science, 382, eadf6249. [CrossRef] [PubMed] [Google Scholar]
  • Amirian, R., Badrbani, M.A, Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S.M., Derakhshankhah, H., Jaymand, M. (2023). Targeted protein modification as a paradigm shift in drug discovery. Eur J Med Chem, 260, 115765. [CrossRef] [PubMed] [Google Scholar]
  • Banik, S.M., Pedram, K., Wisnovsky, S., Ahn, G. Riley, N.M., Bertozzi, C.R. (2020). Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 584, 291-297. [Google Scholar]
  • Bao, J., Chen, Z., Li, Y., Chen, L., Wang, W., Sheng, C., Dong, G. (2023). Discovery of novel PDEδ autophagic degraders: a case study of autophagy-tethering compound (ATTEC). ACS Med Chem Lett, 15, 29-35. [Google Scholar]
  • Bejarano, E., Cuervo, A.M. (2010). Chaperone-mediated autophagy. Proc Am Thorac Soc, 7, 29-39. [CrossRef] [PubMed] [Google Scholar]
  • Békés, M., Langley, D.R., Crews, C.M. (2022). PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov, 21, 181-200. [CrossRef] [PubMed] [Google Scholar]
  • Caianiello, D.F., Zhang M., Ray, J.D., Howell, R.A., Swartzel, J.C., Branham, E.M.J., Chirkin, E., Sabbasani, V.R., Gong, A.Z., McDonald, D.M., Muthusamy, V., Spiegel, D.A. (2021). Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat Chem Biol, 17, 947-953. [Google Scholar]
  • Cassidy, K., Zao, H. (2023). Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy-lysosome pathway. Biochemistry, 62, 580-558. [CrossRef] [PubMed] [Google Scholar]
  • Cheng, W., Li, S., Wen, X., Han, S., Wang, S., Wei, H., Song, Z., Wang, Y., Tian, X., Zhang, X. (2021). Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia. Chem Comm, 57, 12852-12855. [CrossRef] [PubMed] [Google Scholar]
  • Costales, M.G., Aikawa, H., Li, Y., Childs-Disney, J.L., Abegg, D., Hoch, D.G., Velagapudi, S.P., Nakai, Y., Khan, T., Wang, K.W., Yildirim, I., Adibekian, A., Wang, E.T., Disney, M. (2020). Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proc Natl Acad Sci USA, 117, 2406-2411. [Google Scholar]
  • Ding, Y., Xing, D., Fei, Y., Lu, B. (2022). Emerging degrader technologies engaging lysosomal pathways. Chem Soc Rev, 51, 8832-8876. [CrossRef] [PubMed] [Google Scholar]
  • Dong, G., Ding, Y., He, S., Cheng, C. (2021). Molecular glues for targeted protein degradation: from serendipity to rational discovery. J Med Chem, 64, 10606-10620. [CrossRef] [PubMed] [Google Scholar]
  • Drummond, M.L., Henry, A. (2020). Improved accuracy for modeling PROTAC-mediated ternary complex formation and targeted protein degradation via new in silico methodologies. J Chem Inf Model, 60, 5234-5254. [CrossRef] [PubMed] [Google Scholar]
  • Fu, Y., Chen, N., Wang, Z., Luo, S., Ding, Y., Lu, B. (2021). Degradation of lipid droplets by chimeric autophagy-tethering compounds. Cell Res, 31, 965-979. [CrossRef] [PubMed] [Google Scholar]
  • Ghidini, A., Cléry, A., Halloy, F., Allain, F.H.T., Hall, J. (2021). RNA-PROTACs: degraders of RNA-binding proteins. Angew Chem Int Ed Engl, 60, 3163-3169. [CrossRef] [PubMed] [Google Scholar]
  • Ghosh, S., Ramadas, B., Manna, D. (2022). Targeted protein degradation using the lysosomal pathway. RSC Med Chem, 13, 1476. [CrossRef] [PubMed] [Google Scholar]
  • Hansen, J.D., Correa, M., Nagy, M.A., Alexander, M., Plantevin, V., Grant, V., Whitefield, B., Huang, D., Kercher, T., Harris, R., Narla, R.K., Leisten, J., Tang, Y., Moghaddam, M., Ebinger, K., Piccotti, J., Havens, C.G., Cathers, B., Carmichael, J., Daniel, T., Vessey, R., Hamann, L.G., Leftheris, K., Mendy, D., Baculi, F., Lebrun, L.A., Khambatta, G., Lopez-Girona, A. (2020). Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem, 63, 6648-6676. [CrossRef] [PubMed] [Google Scholar]
  • He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., Yu Rao, Y. (2022). PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduc Target Ther, 7, 181. [Google Scholar]
  • Heitel, P. (2023). Emerging TACnology: heterobifunctional small molecules inducers of targeted posttranslational protein modification. Molecules, 28(690), 1-28. [Google Scholar]
  • Henning, N.J., Boike, L., Spradlin, J.N., Ward, C.C., Liu, G., Zhang, E., Bridget, P., Belcher, B.P., Brittain, S.M., Hesse, M.J., Dovala, D., McGregor, L., Valdez Misiolek, R., Plasschaert, L.W., Rowlands, D.J., Wang, F., Franck, A.O., Fuller, D., Estes, A.R., Randall, K.L., Panidapu, A., McKenna, J.M., Tallarico, J.A., Schirle, M., Nomura, D.K. (2022). Deubiquitinase-targeting chimeras for targeted protein stabilization. Nat Chem Biol, 18, 412-421. [Google Scholar]
  • Hines, J., Gough, J.D., Corson, T.W., Crews, C.M. (2013). Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with PhosphoPROTACs. Proc Natl Acad Sci USA, 110, 8942-8947. [CrossRef] [PubMed] [Google Scholar]
  • Huang, X., Wu, F., Jing, Y., Wang, L., Wang, X., Li, X., He, G. (2024). Expanding the horizons of targeted protein degradation: a non-small molecule perspective. Acta Pharmaceutica Sinica B, S2211-3835(24)00013-3, APSB1893. [Google Scholar]
  • Ishida, T., Ciulli, A. (2021). E3 ligases for PROTACs: how they were found and how to discover new ones. SLAS Discovery, 26, 484-502. [CrossRef] [PubMed] [Google Scholar]
  • Ji, C.H., Lee, M.J., Kim, H.Y., Heo, A.J., Park, D.Y., Kim, Y.K., Kim, B.Y., Kwon, Y.T. (2022a). Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera). Autophagy, 18, 2259-2262. [CrossRef] [PubMed] [Google Scholar]
  • Ji, C.H, Kim, H.Y., Lee, M.J., Heo, A.J., Park, D.Y., Lim, S., Shin, S., Ganipisetti, S., Yang, W.S., Jung, C.A., Kim, K.Y., Jeong, E.H., Park, S.H., Bin Kim, S., Lee, S.J., Na, J.E., Kang, J.I., Chi, H.M., Kim, H.T., Kim, Y.K., Kim, B.Y., Kwon, Y.T. (2022b). The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy- lysosome system. Nat Commun, 13, 904. [Google Scholar]
  • Kocaturk, N.M., Gozuacik, D. (2018). Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol, 6, 128. [CrossRef] [PubMed] [Google Scholar]
  • Lee, J., Sung, K.W., Bae, E.J., Yoon D., Kim D., Lee, J.S., Park, D.H., Park, D.Y., Mun, S.R., Kwon, S.C., Kim, H.Y., Min, J.O., Lee, S.J., Suh, Y.H., Kwon, Y.T. (2023). Targeted degradation of α-synuclein aggregates in Parkinson’s disease using AUTOTAC technology. Mol Neurodegener, 18, 41. [CrossRef] [PubMed] [Google Scholar]
  • Li, A.S.M., Kimani, S., Wilson, B., Noureldin, M., González-Álvarez, H., Ahmed Mamai, A., Hoffer, L., Guilinger, J.P., Zhang, Y., von Rechenberg, M., Disch, J.S., Mulhern, C.J., Belinda, L.,Slakman, B.L., W. Cuozzo, J.W., Aiping Dong, A., Poda, G., Mohammed, M., Saraon, P., Manish Mittal, M., Modh, P., Vaibhavi Rathod, V., Patel, B., Ackloo, S., Santhakumar, V., Magdalena M Szewczyk, M.M., Barsyte-Lovejoy, D., Arrowsmith, C.H., Marcellus, R., Guié, M.-A., D. Keefe, A.D., J. Brown, P.J., Levon Halabelian, L., Al-awar, R., Masoud Vedadi, M. (2023). Discovery of nanomolar DCAF1 small molecule ligands. J Med Chem, 66, 5041-5060. [CrossRef] [PubMed] [Google Scholar]
  • Li, J., Chen, X., Lu, A., Liang, C. (2023). Targeted protein degradation in cancers: orthodox PROTACs and beyond. The Innovation, 4, 1-14. [Google Scholar]
  • Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., Han, B. (2023). Application of novel degraders employing autophagy for expediting medicinal research. J Med Chem, 66, 1700-1711. [CrossRef] [PubMed] [Google Scholar]
  • Li, Z., Zhu, C., Ding, Y., Fei, Y., Lu, B. (2020). ATTEC: a potential new approach to target proteinopathies. Autophagy, 16, 185-197. [CrossRef] [PubMed] [Google Scholar]
  • Liu, J., Yu, X., Chen, H., Kaniskan, H.Ü., Xie, L., Chen, X., Jin, J., Wei, W. (2022). TF-DUBTACs stabilize tumor suppressor transcription factors. J Am Chem Soc, 144, 12934-12941. [CrossRef] [PubMed] [Google Scholar]
  • Liu, S., Tong, B., Mason, J.W., Ostrem, J.M., Antonin, A., Hua, B.K., Tang, S.A., Bonazzi, S., Briner, K., Berst, F., Zécri, F.J., Schreiber, S.L. (2023). Rational screening for cooperativity in small-molecule inducers of protein-protein associations. J Am Chem Soc, 145, 23281-23291. [CrossRef] [PubMed] [Google Scholar]
  • Lu, G., Middleton, R.E., Sun, H., Naniong, M.V., Ott, C.J., Mitsiades, C.S., Wong, K.K., Bradner, J.E., Kaelin, W.G. (2014). The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science, 343, 305-309. [CrossRef] [PubMed] [Google Scholar]
  • Mao, W., Vandecan, N.M., Bingham, C.R., Tsang, P.K., Ulintz, P., Sexton, R., Bochar, D.A., Merajver, S.D., Soellner, M.B. (2024). Selective and potent PROTAC degrader of c-Src kinase. ACS Chem Biol, 19, 110-116. [Google Scholar]
  • Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I.H., Hahn, E., Seiler, K., Koren, A., Petzold, G., Fellner, M., Bock, C., Müller, A.C., Zuber, J., Geyer, M., Thomä, N.H., Kubicek, S., Winter, G.E. (2020). Rational discovery of molecular glue degraders via scalable chemical profiling. Nat Chem Bio, 116, 1199-1207. [Google Scholar]
  • Morreale, F.E., Kleine, S., Leodolter, J., Junker, S., Hoi, D.M., Ovchinnikov, S., Okun, A., Juliane Kley, J., Kurzbauer, R., Junk, L., Guha, S., Podlesainski, D., Kazmaier, U., Boehmelt, G., Weinstabl, H., Rumpel, K., Schmiedel, V.M., Markus Hartl, M., Haselbach, D., Meinhart, A., Kaiser, M., Clausen, T. (2022). BacPROTACS mediate targeted protein degradation in bacteria. Cell, 185, 2338-2353. [CrossRef] [PubMed] [Google Scholar]
  • Nalawansha, D.A., Crews, C.M. (2020). PROTACs: an emerging therapeutic modality in precision medecine. Cell Chem Biol, 27, 998-1014. [CrossRef] [PubMed] [Google Scholar]
  • Ng, A., Offensperger, F., Cisneros, J.A., Scholes, N.S., Malik, M., Villanti, L., Rukavina, A., Ferrada, E., Hannich, J.T., Koren, A., Kubicek, S., Superti-Furga, G., Winter, G.E. (2023). Discovery of molecular glue degraders via isogenic morphological profiling. ACS Chem Biol, 18, 2464-2473. [CrossRef] [PubMed] [Google Scholar]
  • Noblejas-López, M.D.M., Nieto-Jimenez, C., Burgos, M., Gómez-Juárez, M., Montero, J.C., Esparís-Ogando, A., Pandiella, A., Galán-Moya, E.M., Ocaña, A. (2019). Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J Exp Clin Cancer Res, 38, 383. [CrossRef] [PubMed] [Google Scholar]
  • Noblejas-López, M.D.M., Tébar-García, D., López-Rosa, R., Alcaraz-Sanabria, A., Cristóbal-Cueto, P., Pinedo-Serrano, A., Rivas-García, L., Galán-Moya, E.M. (2023). TACkling cancer by targeting selective protein degradation. Pharmaceutics, 15, 2442. [CrossRef] [PubMed] [Google Scholar]
  • Paudel, R.R., Dong, L., Chowdhury, R.R., Monroy, E.Y., Wang, J. (2023). Targeted degradation via lysosome. Biochemistry, 62, 564-579. [CrossRef] [PubMed] [Google Scholar]
  • Pei, J., Pan, X., Wang, A., Shuai, W., Bu, F., Tang, P., Zhang, S., Zhang, Y., Wang, G., Ouyang, L. (2021). Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy. Chem Commun, 57, 13194-13197. [CrossRef] [PubMed] [Google Scholar]
  • Qin, L., Dai, H., Wang, J. (2022). Considerations in targeted protein degradation drug discovery and development. Front Chem, 10, 934337. [CrossRef] [PubMed] [Google Scholar]
  • Raina, K., Crews, C.M. (2017). Targeted protein knockdown using small molecule degraders. Curr Opin Chem Biol, 39, 46-53. [CrossRef] [PubMed] [Google Scholar]
  • Rana, S., Mallareddy, J.R., Singh, S., Boghean, L., Natarajan, A. (2021). Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target cyclin-dependent kinase. Cancers, 13, 5506. [CrossRef] [PubMed] [Google Scholar]
  • Reboud-Ravaux, M. (2021a). Le protéasome, la seconde vie d’une cible thérapeutique validée : aspects structuraux et nouveaux inhibiteurs. Biologie Aujourd’hui, 215, 1-23. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  • Reboud-Ravaux, M. (2021b). Dégradation induite des protéines par des molécules PROTAC et stratégies apparentées : développements à visée thérapeutique. Biologie Aujourdhui, 215, 25-43 et 215, 143. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  • Robbins, D.W., Noviski, M., Rountree, M., Tan, M., Brathaban, N., Ingallinera, T., Karr, D.E., Kelly, A., Konst, Z., Ma, J., Tenn-McClellan, A., McKinnell, J., Perez, L., Guiducci, C., Hansen, G., Sands, A. (2021). Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies. Blood, 138(Suppl. 1), 2251. [CrossRef] [Google Scholar]
  • Rossetti, P., Apprato, G., Caron, G., Ermondi, G., Rossi Sebastiano, M. (2024). Degrader TCM: a computational sparing approach for predicting ternary degradation complexes. ACS Med Chem Lett, 15, 45-53. [CrossRef] [PubMed] [Google Scholar]
  • Rui, H., Ashton, K.S., Min, J., Wang, C., Potts, P.R. (2023). Protein-protein interfaces in molecular glue-induced ternary complexes: classification, characterization, and prediction. RSC Chem Biol, 4, 192-215. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Sasso, J.M., Tenchov, R., Wang, D., Johnson, L.S., Wang, X., Zhou, Q.A. (2023). Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry, 62, 601-623. [CrossRef] [PubMed] [Google Scholar]
  • Schapira, M., Calabrese, M.F., Bullock, A.M., Crews, C.M. (2019). Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discovery, 18, 949-963. [Google Scholar]
  • Schreiber, S.L. (2021). The rise of molecular glues. Cell, 184, 3-9. [CrossRef] [PubMed] [Google Scholar]
  • Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., Stachyra, T.M., Thomas, J.R., Begue, D., Khoshouei, M., Lefeuvre, P., Andraos-Rey, R., Chung, B., Ma, R., Pinch, B., Hofmann, A., Schirle, M., Schmiedeberg, N., Imbach, P., Gorses, D., Calkins, K., Bauer-Probst, B., Maschlej, M., Niederst, M., Maher, R., Henault, M., Alford, J., Ahrne, E., Tordella, L., Hollingworth, G., Thomä, N.H., Vulpetti, A., Radimerski, T., Holzer, P., Carbonneau, S., Thoma, C.R. (2024). DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nat Commun, 15, 275. [Google Scholar]
  • Simonetta, K.R., Taygerly, J., Boyle, K., Basham, S.E., Padovani, C., Lou, Y., Cummins, T.J., Yung, S.L., von Soly S.K., Kayser, F., Kuriyan, J., Rape, M., Cardozo, M., Gallop, M.A., Bence, N.F., Barsanti, P.A., Saha, A. (2019). Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat Commun, 10, 1402. [Google Scholar]
  • Tae, H.S., Sundberg, T.B., Neklesa, T.K., Noblin, D.J., Gustafson, J.L., Roth, A.G., Raina, K., Crews, C.M. (2012). Identification of hydrophobic tags for the degradation of stabilized proteins. Chem Bio Chem, 13, 538-541. [CrossRef] [PubMed] [Google Scholar]
  • Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., Arimoto, H. (2019). AUTACs: cargo-specific degraders using selective autophagy. Mol Cell, 76, 797-810. [CrossRef] [PubMed] [Google Scholar]
  • Takahashi, D., Arimoto, H. (2021). Selective autophagy as the basis of autophagy-based degraders. Cell Chem Biol, 28, 1061-1071. [CrossRef] [PubMed] [Google Scholar]
  • Vulpetti, A., Holzer, P., Schmiedeberg, N., Imbach-Weese, P., Pissot-Soldermann, C., Hollingworth, G.J., Radimerski, T., Thoma, C.R., Stachyra, T.-M., Wojtynek, M., Maschlej, M., Chau, S., Schuffenhauer, A., Fernández, C., Schröder, M., Renatus, M. (2023). Discovery of new binders for DCAF1, an emerging ligase target in the targeted protein degradation field. ACS Med Chem Lett, 14, 949-954. [CrossRef] [PubMed] [Google Scholar]
  • Wang, Y., Zheng, J., Long, Y., Wu, W., Zhu, Y. (2024). Direct stabilization of proteins: new horizons in treatment of nonalcoholic steatohepatitis. Biochem Pharm, 220, 115989. [CrossRef] [Google Scholar]
  • Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., Wang, S. (2019). Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders. J Med Chem, 62, 9471-9487. [CrossRef] [PubMed] [Google Scholar]
  • Zaidman, D., Prilusky, J., London, N. (2020). PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes. J Chem Inf Model, 60, 4894-4903. [CrossRef] [PubMed] [Google Scholar]
  • Zhang, L., Riley-Gillis, B., Vijay, P., Shen, Y. (2019). Acquired resistance to BET-PROTACs (Proteolysis-targeting chimeras) caused by genomic alterations in core componenets of E3 ligase complexes. Mol Cancer Ther, 18, 1302-1311. [CrossRef] [PubMed] [Google Scholar]
  • Zhong, J., Zhao, R., Wang, Y., Su, Y.-X., Lan, X. (2023). Nano-PROTACs: state of the art and perspectives. Nanoscale, 16, 4378-4391. [Google Scholar]
  • Zhu, W., Zhang, W., Chen, J., Tong, Y., Xu, F., Pang, J. (2024). Discovery of effective dual PROTAC degraders for neurodegenerative disease-associated aggregates. J Med Chem, 67, 3448-3466. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.